Skip to main content
letter
. 2020 May 22;55(12):2335–2338. doi: 10.1038/s41409-020-0946-x

Fig. 1. Outcome of follicular lymphoma patients after allogeneic stem cell transplantation.

Fig. 1

Nonrelapse mortality (NRM; a), incidence of relapse (RI; b), progression-free survival (PFS; c), and overall survival (OS; d) for patients with idelalisib exposure before allogeneic stem cell transplantation (alloSCT).